34 |
Cancer Research Horizons |
Oncology |
Small molecule |
CDC7 Inhibitors
|
34 |
University of California, San Diego |
Oncology |
Vaccine |
Encapsulation Method of Adenoviral Vectors in Liposomes
|
33 |
University of California, San Diego |
Inflammatory disease |
Small molecule |
Identification of Novel NLRP3 Inflammasome Inhibitors
|
33 |
NIH |
Oncology |
Small molecule |
Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors
|
32 |
Boston University |
Oncology |
Small molecule |
TFCP2 Transcription Factor Inhibitors
|
32 |
University of California, San Diego |
Oncology |
Cell therapy |
Macrophage Programming for Immunotherapy
|
31 |
University of California, San Diego |
Oncology |
Small molecule |
Novel Cyclic Dinucleotide Analogues as STING Agonists
|
31 |
Weill Cornell Medicine |
Oncology |
Antibody Conjugated |
Anti-CDCP1 Antibody-Drug Conjugate for the Treatment of Solid Tumors
|
30 |
Weill Cornell Medicine |
Oncology |
Antibody |
Anti-ART1 Monoclonal Antibody for Improved Anticancer Immunotherapy
|
30 |
The Ohio State University |
Oncology, Hematology |
Small molecule |
HOSU-3, DHODH Inhibitor for Acute Myeloid Leukemia
|
29 |
The Ohio State University |
Oncology |
Small molecule |
AHR Inhibitor for Hematological Malignancies
|
29 |
Stanford SPARK Program |
Oncology |
Antibody |
Enhancing Host-anti-tumor Response by Preventing Thrombin Cleavage of Osteopontin
|
28 |
Ramot At Tel Aviv University |
Oncology |
Peptide |
Therapeutic Targeting of CD45 by Novel Agents to Immunotherapy Non-responders Tumors
|
28 |
The Ohio State University |
Oncology |
Small molecule |
Mps1 Kinase Inhibitors As Mitotic Regulator for Cancer Therapy
|
27 |
The Ohio State University |
Hematology |
Small molecule |
DHODH Inhibitors for Treatment of Hematological Malignancies
|
27 |
Ramot At Tel Aviv University |
Oncology |
Oncolytic Virotherapy |
EHDV-TAU, a Novel Oncolytic Virus
|
26 |
NIH |
Oncology |
Protein |
Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy
|
26 |
The Ohio State University |
Oncology |
Vaccine |
Activated B cells as Therapeutic Cancer Vaccine Platform
|
25 |
The Ohio State University |
Oncology |
Small molecule |
Orally Bioavailable and Brain Penetrant Mps1/TTK inhibitors as cancer therapeutics
|
25 |
FDA Technology Transfer |
Oncology |
Antibody |
Chimeric Immunotoxins Targeting IL-13Rα2 Positive Human Cancers
|